Skip to main content

Jefferies Keeps Their Buy Rating on Incyte (INCY)

Tipranks - Tipranks - Thu Feb 12, 9:06AM CST

In a report released today, from Jefferies maintained a Buy rating on Incyte, with a price target of $120.00.

Valentine's Day Sale - 70% Off

In addition to Jefferies, Incyte also received a Buy from TipRanks – xAI’s xAi Biotechnology in a report issued today. However, on the same day, BMO Capital reiterated a Sell rating on Incyte (NASDAQ: INCY).

See today’s best-performing stocks on TipRanks >>

Based on Incyte’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.37 billion and a net profit of $424.17 million. In comparison, last year the company earned a revenue of $1.14 billion and had a net profit of $106.46 million

Based on the recent corporate insider activity of 105 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year. Last month, Mohamed Khairie Issa, the EVP, Head of US Oncology of INCY sold 19,120.00 shares for a total of $2,065,502.16.

Read More on INCY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).